SN has been the topic of several other reports. Credit Suisse Group upped their price objective on shares of Smith & Nephew from GBX 1,285 ($18.16) to GBX 1,290 ($18.23) and gave the stock a neutral rating in a report on Friday, February 9th. HSBC upgraded shares of Smith & Nephew to a buy rating and upped their price objective for the stock from GBX 1,320 ($18.66) to GBX 1,530 ($21.63) in a report on Monday, March 26th. JPMorgan Chase restated an overweight rating and issued a GBX 1,411 ($19.94) price objective on shares of Smith & Nephew in a report on Wednesday, February 7th. Finally, Morgan Stanley decreased their price objective on shares of Smith & Nephew from GBX 1,558 ($22.02) to GBX 1,457 ($20.59) and set an equal weight rating on the stock in a report on Tuesday, February 13th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of Hold and an average price target of GBX 1,355.33 ($19.16).
LON:SN traded down GBX 1 ($0.01) on Thursday, hitting GBX 1,325 ($18.73). The stock had a trading volume of 576,997 shares, compared to its average volume of 3,250,000. Smith & Nephew has a 1-year low of GBX 1,173 ($16.58) and a 1-year high of GBX 1,442 ($20.38).
The firm also recently announced a dividend, which will be paid on Wednesday, May 9th. Shareholders of record on Thursday, April 5th will be issued a dividend of $0.23 per share. The ex-dividend date is Thursday, April 5th. This is a positive change from Smith & Nephew’s previous dividend of $0.12. This represents a yield of 1.34%.
In other news, insider Graham Baker acquired 1,000 shares of the company’s stock in a transaction on Tuesday, February 27th. The shares were bought at an average cost of GBX 1,283 ($18.13) per share, with a total value of £12,830 ($18,134.28). Also, insider Olivier Bohuon sold 8,171 shares of the stock in a transaction that occurred on Wednesday, March 7th. The shares were sold at an average price of GBX 1,301 ($18.39), for a total transaction of £106,304.71 ($150,254.01).
About Smith & Nephew
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.